Entering text into the input field will update the search result below

Inovio Pharmaceuticals, Inc. (INO) Q4 2022 Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET

Company Participants

Thomas Hong - Manager-Investor Communications

Jacqueline Shea - President and Chief Executive Officer

Michael Sumner - Chief Medical Officer

Peter Kies - Chief Financial Officer

Conference Call Participants

Hartaj Singh - Oppenheimer

Charlie Young - Bank of America

Yi Chen - H.C. Wainwright


Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead.

Thomas Hong

Good afternoon, and thank you for joining the Inovio 2022 Fourth Quarter and Full Year Financial Results Conference Call. Joining me on today's call are Dr. Jacque Shea, President and CEO; and Dr. Michael Sumner, Chief Medical Officer; and Mr. Peter Kies, Chief Financial Officer. We also have other members of Innovia's leadership here with us today, who will be part of our Q&A session.

Today's call will review our corporate and financial information for the quarter and year ended December 31, 2022, as well as provide an update on our efforts to develop our DNA medicines platform. Following prepared remarks, we will conduct a question-and-answer segment.

During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Inovio's DNA medicines platform, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters. All of these statements are based on the beliefs and expectations of management as of today.

Actual events or results could differ materially. We refer you to the documents we file from time to time with the

Recommended For You

Comments (1)

Half the world's hungry could have been fed with the money wasted by this profligate and useless sham of a biotech.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.